BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Surowka M, Schaefer W, Klein C. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs 2021;13:1967714. [PMID: 34491877 DOI: 10.1080/19420862.2021.1967714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Natoli M, Hatje K, Gulati P, Junker F, Herzig P, Jiang Z, Davydov II, Germann M, Trüb M, Marbach D, Zwick A, Weber P, Seeber S, Wiese M, Lardinois D, Heinzelmann-Schwarz V, Rosenberg R, Tietze L, Mertz KD, Umaña P, Klein C, Codarri-Deak L, Kao H, Zippelius A. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors. J Immunother Cancer 2022;10:e005548. [PMID: 36319064 DOI: 10.1136/jitc-2022-005548] [Reference Citation Analysis]
2 Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci 2022;23:9424. [PMID: 36012690 DOI: 10.3390/ijms23169424] [Reference Citation Analysis]
3 Chen J, Huang C, Zhao W, Ren J, Ji F, Jia L. SnoopLigase Enables Highly Efficient Generation of C-C-Linked Bispecific Nanobodies Targeting TNF-α and IL-17A. Bioconjug Chem 2022. [PMID: 35938675 DOI: 10.1021/acs.bioconjchem.2c00143] [Reference Citation Analysis]
4 Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell 2022;185:2789-805. [PMID: 35868279 DOI: 10.1016/j.cell.2022.05.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, Kobold S. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors. J Immunother Cancer 2022;10:e005054. [PMID: 35902133 DOI: 10.1136/jitc-2022-005054] [Reference Citation Analysis]
6 Shin HG, Yang HR, Yoon A, Lee S. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. Int J Mol Sci 2022;23:5686. [PMID: 35628495 DOI: 10.3390/ijms23105686] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
7 Aghanejad A, Bonab SF, Sepehri M, Haghighi FS, Tarighatnia A, Kreiter C, Nader ND, Tohidkia MR. A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors. Int J Biol Macromol 2022;207:592-610. [PMID: 35296439 DOI: 10.1016/j.ijbiomac.2022.03.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
8 Grunert I, Heinrich K, Ernst J, Hingar M, Briguet A, Leiss M, Wuhrer M, Reusch D, Bulau P. Detailed Analytical Characterization of a Bispecific IgG1 CrossMab Antibody of the Knob-into-Hole Format Applying Various Stress Conditions Revealed Pronounced Stability. ACS Omega 2022;7:3671-9. [PMID: 35128275 DOI: 10.1021/acsomega.1c06305] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs 2022;14:2014296. [PMID: 35030985 DOI: 10.1080/19420862.2021.2014296] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 50.0] [Reference Citation Analysis]